- cafead   Apr 15, 2021 at 10:12: AM
via Roche’s Genentech unit has released further data from a key trial of Evrysdi, its oral treatment for spinal muscular atrophy (SMA), the rare muscle wasting disease that is often fatal in babies that develop it.
article source
article source